Mortality surrogates in combined pulmonary fibrosis and emphysema

Abstract

When assessing disease progression in IPF, <i>D</i> _LCO decline should be considered in patients with ≥10% emphysema and a ≥5% 1-year relative FVC decline threshold considered in non-CPFE IPF patients.